GSK’s Seroxat pay-for-delay deals may restrict competition: AG

GlaxoSmithKline (GSK) may have restricted competition by making a deal with generic drugmakers to delay the launch of copies of an antidepressant, according to an adviser to the Court of Justice of the European Union (CJEU).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Africa

GSK fined £37m for ‘anti-competitive’ conduct

12 February 2016 GSK has been fined more than £37 million by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat.

Big Pharma

OFT accuses GSK of market abuse over pay-for-delay deals

19 April 2013 The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.

Big Pharma

CJEU issues clarification on UK’s pay-for-delay generics ruling

31 January 2020 The Court of Justice of the European Union has ruled that pharmaceutical pay-for-delay agreements may violate the Treaty on the Functioning of the European Union, in comments passed down on January 30, 2020.

More on this story

Africa

GSK fined £37m for ‘anti-competitive’ conduct

12 February 2016 GSK has been fined more than £37 million by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat.

Big Pharma

OFT accuses GSK of market abuse over pay-for-delay deals

Big Pharma

CJEU issues clarification on UK’s pay-for-delay generics ruling

More on this story

Africa

GSK fined £37m for ‘anti-competitive’ conduct

12 February 2016 GSK has been fined more than £37 million by the UK government for “anti-competitive conduct” in relation to ‘pay for delay’ deals centring on anti-depressant drug Seroxat.

Big Pharma

OFT accuses GSK of market abuse over pay-for-delay deals

Big Pharma

CJEU issues clarification on UK’s pay-for-delay generics ruling